Table 3—

Summary of interferon-γ release assay and tuberculin skin test (TST) results in children with active tuberculosis (TB) and latent tuberculosis infection (LTBI)

TST mmQFG-ITT-SPOT.TB
≥15≥10<6Pos.Neg.Ind.Pos.Neg.TF
Active TB
 Definite20/24 (83.3)21/24 (87.5)2/24 (8.3)20/25 (80.0)3/25 (12.0)2/25 (8.0)14/24 (58.3)9/24 (37.5)1/24 (4.2)
 Probable17/38 (44.7)24/38 (63.1)9/38 (23.6)20/38 (52.6)16/38 (42.1)2/38 (5.2)17/38 (44.7)17/38 (44.7)4/38 (10.5)
 Definite and probable38/63 (60.3)45/63 (71.4)12/63 (19.0)40/63 (63.5)18/63 (28.5)4/63 (6.3)31/62 (50.0)26/62 (41.9)5/62 (8.0)
 Possible2/28 (7.1)5/28 (17.8)22/28 (78.5)2/28 (7.1)22/28 (78.5)4/28 (14.2)3/28 (10.7)22/28 (78.5)3/28 (10.7)
LTBI
 BCG vaccinated38/84 (45.2)51/84 (60.7)59/84 (70.2)28/87 (32.1)53/87 (60.9)6/87 (6.9)25/85 (29.4)51/85 (60.0)9/85 (10.6)
 Not BCG vaccinated14/30 (46.7)17/30 (56.7)19/30 (63.3)10/31 (32.2)21/31 (67.8)0/31 (0.0)11/31 (35.5)19/31 (61.3)1/31 (3.2)
  • Data are presented as n (%).QFG-IT: QuantiFERON-TB Gold In-tube system (Cellestis, Carnegie, Australia); pos.: positive; neg.: negative; ind.: indeterminate result; TF: test failure; BCG: bacillus Calmette–Guérin. T-SPOT.TB is manufactured by Oxford Immunotec, Abingdon, UK.